Pentobarbital will reduce the extent or effect of zonisamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Not known. Avoid; coadministration with CYP3A inducers may well cause decreased plasma concentrations of elvitegravir and/or simply a concomitantly administered protease inhibitor and bring on loss of therapeutic outcome and also to possible... https://jessez577ofv9.wikiadvocate.com/user